Cellectis announces the closing of €20.5 M share capital increase subscribed on March 24, 2014 by U.S. Biotechnology Specialist Institutional Investors
Published on March 31, 2014
Paris, France, March 31, 2014 - Cellectis SA (Alternext: ALCLS.PA) announces the successful closing of the €20,520,000 share capital increase subscribed on March 24, 2014 by U.S. biotechnology institutional investors.
OrbiMed Healthcare Fund Management is the main subscriber of the private placement in which venBio, Ridgeback Capital Management, Aquilo Capital Management and Merlin Nexus, inter alia, also purchased new shares. None of these subscriptions reach 5% of Cellectis’s share capital.
Following this transaction, Cellectis’ share capital increased to €1,254,115.85 divided into 25,082,317 shares, thus diluting the existing shareholders by approximately 16% without impacting the main shareholders’ list.
Cellectis points out that this capital increase will be used for the acceleration of innovation in T cells genome engineering in order to provide them with new properties and the enhancement of the structures and function of antigenic chimeric receptor (CAR), and the self-developments of the company’s proprietary T cell CAR portfolio dedicated to the treatment of leukemia and solid tumors.
Trout Capital acted as placement agent in this transaction.